Adial Pharmaceuticals ADIL 深 沪
已收盘 08-01 16:00:00 美东时间
0.4551
+0.019
+4.36%
华盛通- 最 高0.48
- 今 开0.39
- 成交量 204.86万股
- 最 低 0.389
- 昨 收 0.4361
- 总市值 717.96万
- 52周最高 1.30
- 市盈率 静 --
- 换手率 12.99%
- 52周最低 0.22
- 委 比 -33.33%
- 总股本 1577.59万
- 历史最高 236.00
- 量 比 0.18
- 振 幅 20.87%
- 历史最低 0.22
- 每 手 1
- 风险率 0.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adial Pharmaceuticals Enters New Sales Agreement
An announcement from Adial Pharmaceuticals ( ($ADIL) ) is now available. On Aug...
08-02 05:18
Adial Pharmaceuticals Approves Share Increase at Annual Meeting
Adial Pharmaceuticals ( ($ADIL) ) has provided an announcement. On August 1, 20...
08-02 04:59
Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement
Adial Pharmaceuticals announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1), maintaining stockholders' equity of at least $2.5 million. CEO Cary Claiborne highlighted this as a key step in reinforcing investor confidence and supporting long-term growth, reflecting disciplined financial management. The公司 focuses on developing treatments for addiction, with its lead product AD04 showing promise in reducing heavy drinking in AUD p...
07-16 12:30
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
Adial Pharmaceuticals filed an updated provisional patent application for its lead drug AD04, designed to treat Alcohol Use Disorder in heavy drinkers. The patent, expected to be granted, will protect the company's core assets until at least 2045. AD04, a genetically targeted serotonin-3 receptor antagonist, showed promising results in reducing alcohol consumption in heavy drinkers during the pivotal Phase 3 ONWARD trial. The company aims to adva...
07-09 12:30
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Adial Pharmaceuticals (NASDAQ:ADIL) stock moved upwards by 19.6% to $0...
06-26 05:06
Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
Adial Pharmaceuticals has entered agreements with Thermo Fisher Scientific and Cambrex to produce AD04, a drug targeting Alcohol Use Disorder, supporting clinical trials and FDA NDA submission. Thermo Fisher and Cambrex provide manufacturing services and development capabilities, crucial for meeting regulatory requirements and future commercial demands.
06-25 12:30
Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Shares of Nektar Therapeutics (NASDAQ:NKTR) rose sharply in today's pre-market ...
06-24 18:38
Adial Pharmaceuticals announces pricing of $3.6M public offering
Adial Pharmaceuticals (NASDAQ:ADIL) on Tuesday announced the pricing of its public offering for the purchase and sale of 11.1M shares of common stock of the company, together with Series D warrants to...
06-17 20:52
Why Lennar Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Lennar Corporation (NYSE:LEN) rose sharply in today's pre-market trad...
06-17 17:51
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering
Adial Pharmaceuticals announced a public offering of 11.1 million shares of common stock, alongside Series D and E warrants, expecting gross proceeds of $3.6 million. The Series D warrants have a $0.35 exercise price, expiring five years after stockholder approval, while Series E warrants expire in 18 months. The company plans to use proceeds for working capital and general corporate purposes. Adial also amended existing Series B-1 and C-1 warran...
06-17 12:00
